Home » ETF » PBE

PBE - Invesco Dynamic Biotechnology & Genome ETF

Stock Price: $75.24 USD -0.30 (-0.39%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Assets $299.93M
NAV $75.55
Expense Ratio 0.58%
PE Ratio 51.90
Beta (5Y) 1.08
Dividend (ttm) n/a
Dividend Yield n/a
Ex-Dividend Date Mar 23, 2020
1-Year Return -
Trading Day April 16
Last Price $75.24
Previous Close $75.54
Change ($) -0.30
Change (%) -0.39%
Day's Open 76.67
Day's Range 74.24 - 76.67
Day's Volume 5,367
52-Week Range 51.07 - 84.86

Fund Description

The investment seeks to track the investment results (before fees and expenses) of the Dynamic Biotech & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Asset Class
Equity
Sector
Biotech
Region
North America
Inception Date
Jun 23, 2005
Exchange
NYSEARCA
Ticker Symbol
PBE
Index Tracked
Dynamic Biotechnology & Genome Intellidex Index

Top 10 Holdings

48.41% of assets
NameSymbolWeight
Bio-TechneTECH5.62%
AmgenAMGN5.55%
QiagenQGEN5.18%
Alexion PharmaceuticalsALXN5.07%
SeagenSGEN4.93%
CatalentCTLT4.89%
BioMarin PharmaceuticalBMRN4.76%
IlluminaILMN4.46%
Five Prime TherapeuticsFPRX4.44%
Intellia TherapeuticsNTLA3.51%
View All Holdings

Dividends

Ex-DividendAmountPay Date
Mar 23, 2020$0.029Mar 31, 2020
Sep 24, 2018$0.002Sep 28, 2018
Jun 16, 2017$0.215Jun 30, 2017
Mar 17, 2017$0.056Mar 31, 2017
Dec 16, 2016$0.121Dec 30, 2016
Sep 16, 2016$0.028Sep 30, 2016
Full Dividend History

News

Hide News
  • All
  • Videos
  • Conversation

Many would like to follow Ark Investment Management founder Cathie Wood's vision due to her success. She says that digital wallets and genomics will be the next two biggest disruptive trends after Tesla...

Other tickers mentioned: ARKK, ARKW, BATT, DRIV, IPAY
4 days ago - Zacks Investment Research

The coronavirus pandemic could be a long-term positive for biopharma companies and the Invesco Dynamic Biotechnology & Genome ETF (PBE). PBE tracks the Dynamic Biotech & Genome Intellidex Index, which “...

2 months ago - ETF Trends

The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.

Other tickers mentioned: ARKG, BBH, BNTX, BTEC, CNCR, FBT, IBB ...
3 months ago - Zacks Investment Research

Sector ETF report for PBE

3 months ago - Zacks Investment Research

AstraZeneca has agreed to buy rare-disease specialist Alexion Pharmaceuticals for $39 billion. The deal would represent the biggest transaction in pharmaceuticals since 2019.

Other tickers mentioned: BBH, FBT, PJP, PPH
4 months ago - Zacks Investment Research

The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when AstraZeneca (NYSE: AZN) announced a $39-billion takeover of Alexion ...

Other tickers mentioned: BBH, FBT
4 months ago - Benzinga

Biotech stocks are likely to remain in focus through year end amid news surrounding COVID-19 vaccines and treatments.

Other tickers mentioned: IBB
4 months ago - Investopedia

Sector ETF report for PBE

5 months ago - Zacks Investment Research

Wall Street booked remarkable gains a day after the election on hopes of a divided Congress.

Other tickers mentioned: EMQQ, KWEB, RWGV, WCLD, XBI
5 months ago - Zacks Investment Research

With Regeneron Pharmaceuticals and Eli Lilly & Company requesting the FDA for an Emergency Use Authorization for their antibody therapy treatments, the biotech space is filled with optimism.

Other tickers mentioned: ARKG, BBH, IBB, XBI
6 months ago - Zacks Investment Research

The announcement of the 2020 Nobel Prize winners for Chemistry has successfully brought investor attention to the gene-editing space.

Other tickers mentioned: ARKG, GNOM, IDNA
6 months ago - Zacks Investment Research

The progress in Trump's health condition and his treatment protocols are continuously under the purview of market participants and are impacting Wall Street movements.

Other tickers mentioned: ARKG, BBH, IBB, XBI
6 months ago - Zacks Investment Research

After setting scintillating paces earlier this thanks to the race to develop a coronavirus vaccine, some health care exchange-traded funds are languishing.

Other tickers mentioned: BTEC, PTH
6 months ago - Benzinga

Sector ETF report for PBE

6 months ago - Zacks Investment Research

Biotech ETFs are, in a word, hot.

Other tickers mentioned: BTEC, CNCR, GERM, IBB, XBI
8 months ago - Kiplinger

In a sea of red stocks on Wednesday, as fear grips markets due to another spike in coronavirus cases throughout the country, Gilead Sciences is one of the few bright spots in the stock market.

Other tickers mentioned: BBH, IBB
9 months ago - ETF Trends

Here we highlight some ETFs for gaining exposure to the genomics market that is currently buzzing with opportunities for investors to cash on.

Other tickers mentioned: ARKG, GNOM, IDNA
10 months ago - Zacks Investment Research

The rising incidence of cancer cases has encouraged several major pharmaceutical and biotech players to invest substantially in the developments of drugs.

Other tickers mentioned: CNCR, IBB, XBI
11 months ago - Zacks Investment Research

As the coronavirus continues to spread, the latest positive data on remdesivir is some relief in such challenging times.

Other tickers mentioned: BBH, IBB, XBI
11 months ago - Zacks Investment Research

Pacer Financial has filed for Pacer BioThreat ETF to enjoy the first-mover advantage that provide investors an option to capitalize on the new opportunities triggered by coronavirus.

Other tickers mentioned: ARKG, SBIO
11 months ago - Zacks Investment Research

Biotech and healthcare ETFs were pretty stable on Apr 23 despite the news that Gilead's Remdesivir failed to improve Covid-19 patients' condition.

Other tickers mentioned: BBH, CNCR, FBT, IBB, IDNA, IHE, IHF ...
11 months ago - Zacks Investment Research

These biotech ETFs could be standouts again in 2020, particularly if genomics stocks rally

Other tickers mentioned: ARKG, BBC
1 year ago - InvestorPlace

Can biotech ETFs repeat its success story of 2019 in the election year of 2020?

Other tickers mentioned: BBC, CNCR, HTEC, IBB, IDNA, SBIO, XBI
1 year ago - Zacks Investment Research

Discover why biotech stocks are surging despite large fund outflows. Monitor these three industry ETFs for "buy the dip" opportunities.

Other tickers mentioned: LABU, XBI
1 year ago - Investopedia

Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to work in favor of the biotech market.

Other tickers mentioned: ARKG, BBH, BBP, BTEC, CNCR, FBT, IBB ...
1 year ago - Zacks Investment Research

The release of encouraging data on the CRISPR/Cas9 gene-editing therapy CTX001 for two severe blood disorders puts emphasis on some genomic ETFs.

Other tickers mentioned: ARKG, GNOM
1 year ago - Zacks Investment Research

Decent fundamentals and valuations as well as encouraging developments put these medical ETFs and stocks in focus.

Other tickers mentioned: ARKG, CNCR, PTH, XBI
1 year ago - Zacks Investment Research

Many biotech ETFs and other funds have fallen sharply off their highs in recent months.

Other tickers mentioned: IBB, XBI
1 year ago - Investopedia

Rising investments, surging demand for personalized medicines and shrinking sequencing costs are a slew of factors favouring the genomics space. We look at a few ETFs that can cash in on this trend.

Other tickers mentioned: ARKG, INDA
1 year ago - Zacks Investment Research

Amgen agreed to buy psoriasis and psoriatic arthritis drug Otezla from Celgene for $13.4 billion in cash.

Other tickers mentioned: BBH, IBB, IEIH, PJP
1 year ago - Zacks Investment Research

Most of the financial markets have trended lower in recent weeks, but biotech seems to have countered the trend.

Other tickers mentioned: INCY, IONS
1 year ago - Investopedia

The healthcare sector has been the worst performing on the S&P 500 in 2019, but these biotech ETFs are still worth a look.

Other tickers mentioned: ARKG, PSCH, SBIO, XBI
1 year ago - InvestorPlace

Pfizer struck a deal to acquire the cancer drugmaker Array Biopharma for $11 billion in an all-cash consideration.

Other tickers mentioned: ARKG, SBIO, XBI
1 year ago - Zacks Investment Research

Sector ETF report for PBE

1 year ago - Zacks Investment Research